ApoA1 is known to suppress neutrophil activation and inhibit endothelial expression of adhesion molecules (169) and its downregulation may thus lead to HCC, indicating its role as a possible biomarker for HCC diagnosis, prognosis, and monitoring. Here, APOA1 is linked to hepatocellular carcinoma.